Literature DB >> 26123463

Malignant mixed Mullerian tumour of uterus secondary to tamoxifen therapy for hormone responsive breast cancer.

Mayank Gupta1, Kala Gnanasekaran Kiruthiga1.   

Abstract

Tamoxifen is used in the treatment of hormone responsive breast cancer because of its antiestrogenic effect. However, it also has an estrogenic effect on the uterus, thereby increasing the risk of endometrial hyperplasia, endometrial polyp and endometrial neoplasms such as endometrial adenocarcinoma and malignant mixed Mullerian tumour (MMMT). This case describes the possible pathogenesis and risk of developing MMMT due to long-term tamoxifen intake in hormone responsive breast cancer. 2015 BMJ Publishing Group Ltd.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26123463      PMCID： PMC4488633          DOI： 10.1136/bcr-2015-209981

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN： 1757-790X


  12 in total

1.  PCR display identifies tamoxifen induction of the novel angiogenic factor adrenomedullin by a non estrogenic mechanism in the human endometrium.

Authors:  Y Zhao; S Hague; S Manek; L Zhang; R Bicknell; M C Rees
Journal:  Oncogene       Date:  1998-01-22       Impact factor: 9.867

Review 2.  Tamoxifen and malignant epithelial-nonepithelial tumours of the endometrium: report of six cases and review of the literature.

Authors:  T Treilleux; H Mignotte; C Clement-Chassagne; P Guastalla; C Bailly
Journal:  Eur J Surg Oncol       Date:  1999-10       Impact factor: 4.424

Review 3.  Uterine carcinosarcoma.

Authors:  Sherif A El-Nashar; Andrea Mariani
Journal:  Clin Obstet Gynecol       Date:  2011-06       Impact factor: 2.190

4.  Pathology of endometrium treated with tamoxifen.

Authors:  S M Ismail
Journal:  J Clin Pathol       Date:  1994-09       Impact factor: 3.411

5.  Requirement of the Akt/beta-catenin pathway for uterine carcinosarcoma genesis, modulating E-cadherin expression through the transactivation of slug.

Authors:  Makoto Saegusa; Miki Hashimura; Takeshi Kuwata; Isao Okayasu
Journal:  Am J Pathol       Date:  2009-04-23       Impact factor: 4.307

Review 6.  The effects of tamoxifen on the female genital tract.

Authors:  Elzbieta Senkus-Konefka; Tomasz Konefka; Jacek Jassem
Journal:  Cancer Treat Rev       Date:  2004-05       Impact factor: 12.111

7.  Evidence for a common etiology for endometrial carcinomas and malignant mixed mullerian tumors.

Authors:  A Zelmanowicz; A Hildesheim; M E Sherman; S R Sturgeon; R J Kurman; R J Barrett; M L Berman; R Mortel; L B Twiggs; G D Wilbanks; L A Brinton
Journal:  Gynecol Oncol       Date:  1998-06       Impact factor: 5.482

8.  Uterine adenosarcoma in a patient with history of breast cancer and long-term tamoxifen consumption.

Authors:  Ali Akhavan; Mahmood Akhavan Tafti; Farhad Aghili; Hossein Navabii
Journal:  BMJ Case Rep       Date:  2012-10-19

9.  Carboplatin-Paclitaxel versus Cisplatin-Ifosfamide in the treatment of uterine carcinosarcoma: a retrospective cohort study.

Authors:  Domenica Lorusso; Fabio Martinelli; Maria Mancini; Italo Sarno; Antonino Ditto; Francesco Raspagliesi
Journal:  Int J Gynecol Cancer       Date:  2014-09       Impact factor: 3.437

10.  Prognostic features of surgical stage I uterine carcinosarcoma.

Authors:  Sarah E Ferguson; Carmen Tornos; Amanda Hummer; Richard R Barakat; Robert A Soslow
Journal:  Am J Surg Pathol       Date:  2007-11       Impact factor: 6.394
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.